NYSEAMERICAN:PHGE BiomX (PHGE) Stock Price, News & Analysis $0.53 +0.02 (+4.83%) As of 02:46 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartHeadlinesSEC FilingsShort InterestBuy This Stock About BiomX Stock (NYSEAMERICAN:PHGE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BiomX alerts:Sign Up Key Stats Today's Range$0.51▼$0.5450-Day Range$0.38▼$0.6552-Week Range$0.34▼$1.16Volume255,883 shsAverage Volume1.86 million shsMarket Capitalization$14.17 millionP/E RatioN/ADividend YieldN/APrice Target$15.00Consensus RatingBuy Company Overview BiomX Inc. is a clinical-stage biotechnology company that specializes in developing precision bacteriophage therapies to target pathogenic bacteria in the human microbiome. By harnessing the natural ability of bacteriophages to selectively infect and lyse harmful bacterial strains, BiomX aims to restore microbial balance without disrupting beneficial commensal organisms. The company’s platform integrates phage discovery, formulation and genetic engineering to create tailored phage cocktails for a range of microbiome-associated diseases. The company’s pipeline includes lead clinical candidates for gastrointestinal disorders such as pouchitis and ulcerative colitis, as well as programs addressing dermatological indications including acne and atopic dermatitis. Preclinical studies have demonstrated the ability of BiomX’s phage preparations to reduce targeted bacterial populations implicated in inflammation and disease progression. Advanced product characterization and manufacturing processes support both oral and topical delivery formats, positioning BiomX to advance multiple candidates through regulatory pathways. Founded in 2016 as a spin-out from MIGAL – Galilee Research Institute, BiomX is headquartered in Rehovot, Israel, with a U.S. presence in Cambridge, Massachusetts. The company conducts clinical trials across North America and Europe, collaborating with academic medical centers and contract research organizations. Since its initial public listing on the NYSE American exchange under the ticker PHGE, BiomX has expanded its leadership team to include executives with deep expertise in phage biology, clinical development and biomanufacturing. The company’s research and development efforts are overseen by CEO Eliora Ron, who guides strategic initiatives to translate microbiome science into targeted, next-generation therapies.AI Generated. May Contain Errors. Read More BiomX Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks43rd Percentile Overall ScorePHGE MarketRank™: BiomX scored higher than 43% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingBuy Consensus RatingBiomX has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Upside PotentialBiomX has a consensus price target of $15.00, representing about 2,784.6% upside from its current price of $0.52.Amount of Analyst CoverageBiomX has only been the subject of 1 research reports in the past 90 days.Read more about BiomX's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for BiomX are expected to decrease in the coming year, from ($2.77) to ($2.92) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BiomX is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BiomX is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiomX has a P/B Ratio of 1.73. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about BiomX's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.68% of the float of BiomX has been sold short.Short Interest Ratio / Days to CoverBiomX has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BiomX has recently decreased by 67.65%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBiomX does not currently pay a dividend.Dividend GrowthBiomX does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.68% of the float of BiomX has been sold short.Short Interest Ratio / Days to CoverBiomX has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BiomX has recently decreased by 67.65%, indicating that investor sentiment is improving significantly. News and Social Media0.6 / 5News SentimentN/A Search Interest12 people have searched for PHGE on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added BiomX to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, BiomX insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.00% of the stock of BiomX is held by insiders.Percentage Held by Institutions40.57% of the stock of BiomX is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BiomX's insider trading history. Receive PHGE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BiomX and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PHGE Stock News HeadlinesBiomX announces U.S. FDA placed clinical hold on Phase 2b trial of BX004August 19, 2025 | msn.comBiomX Faces FDA Hold on Phase 2b StudyAugust 19, 2025 | tipranks.comTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.September 19 at 2:00 AM | Porter & Company (Ad)BiomX Inc: BiomX Provides Update on BX004 Phase 2b Trial for the Treatment of Patients with Cystic FibrosisAugust 19, 2025 | finanznachrichten.deBiomX Inc. (AMEX:PHGE) Q2 2025 Earnings Call TranscriptAugust 14, 2025 | msn.comBiomX Inc. Reports Q2 2025 Progress and FinancialsAugust 14, 2025 | msn.comBiomX Publishes Promising Phase 1b/2a Trial ResultsJuly 8, 2025 | tipranks.comBiomX Highlights Progress in Phage Therapy AdvancementsJune 9, 2025 | tipranks.comSee More Headlines PHGE Stock Analysis - Frequently Asked Questions How have PHGE shares performed this year? BiomX's stock was trading at $0.5870 at the beginning of 2025. Since then, PHGE shares have decreased by 11.4% and is now trading at $0.52. How were BiomX's earnings last quarter? BiomX Inc. (NYSEAMERICAN:PHGE) announced its quarterly earnings results on Tuesday, November, 14th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.10) by $0.03. How do I buy shares of BiomX? Shares of PHGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of BiomX own? Based on aggregate information from My MarketBeat watchlists, some other companies that BiomX investors own include Moderna (MRNA), T2 Biosystems (TTOO), Chegg (CHGG), Aldeyra Therapeutics (ALDX), Nokia (NOK), Avino Silver & Gold Mines (ASM) and Anavex Life Sciences (AVXL). Company Calendar Last Earnings11/14/2023Today9/19/2025Next Earnings (Estimated)11/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry MED PRODUCTS Sub-IndustryPharmaceutical Products Current SymbolNYSEAMERICAN:PHGE CIK1739174 Webwww.biomx.com Phone972-7-2394-2377FaxN/AEmployees120Year FoundedN/APrice Target and Rating Average Price Target for BiomX$15.00 High Price Target$15.00 Low Price Target$15.00 Potential Upside/Downside+2,848.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($3.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$17.73 million Net MarginsN/A Pretax MarginN/A Return on Equity-621.75% Return on Assets-103.53% Debt Debt-to-Equity RatioN/A Current Ratio2.66 Quick Ratio2.66 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.30 per share Price / Book1.70Miscellaneous Outstanding Shares26,560,000Free Float25,758,000Market Cap$13.51 million OptionableN/A Beta1.39 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NYSEAMERICAN:PHGE) was last updated on 9/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BiomX Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BiomX With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.